Mpox prevention and orthopoxvirus immunisation
Research activity is centred on prevention of monkeypox (mpox) infection, with attention to mpox virus immunity, vaccine-induced protection, and population-level preparedness against orthopoxvirus exposure.
- Mpox vaccine protection
- Orthopoxvirus immune response
- Infection prevention
The sponsor’s clinical focus includes evaluation of humoral immune response and protective immunity in vaccinated groups relevant to public health readiness.
Vaccine immunogenicity and booster strategies
Clinical interest extends to booster vaccination approaches designed to strengthen immune memory after prior primary vaccination, with emphasis on measurable antibody response after revaccination.
- Booster dose immunogenicity
- Humoral immunity
- Post-vaccination protection
This area reflects a focus on maintaining vaccine-derived defence in settings where sustained protection against mpox is important.
Intradermal and subcutaneous vaccination
Work in this domain compares intradermal and subcutaneous routes of administration for vaccine booster delivery, with interest in immune recognition and tolerability across different injection methods.
- Route of administration
- Intradermal booster
- Subcutaneous booster
The research landscape includes assessment of how administration route relates to detectable immune response in previously vaccinated individuals.
Vaccine safety and reactogenicity
Another key area is vaccine safety, including monitoring of reactogenicity and tolerability after booster immunisation in adults receiving MVA-BN vaccine.
- Safety monitoring
- Reactogenicity
- Booster tolerability
This supports clinical interest in balancing immune response with acceptable safety outcomes during mpox prevention efforts.
Public health preparedness and multisite collaboration
The sponsor’s research activity involves coordinated work across collaborating research sites in multiple countries, aligning infectious disease surveillance, vaccine evaluation, and readiness for emerging transmission risks.
- Multinational trial coordination
- Infectious disease preparedness
- Cross-site vaccine evaluation
These interests are closely tied to public health responses for controlling mpox and supporting targeted immunisation strategies.
